Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study

Claus Roehrborn, Jack Barkin, Steven N. Gange, Neal D. Shore, Jonathan L. Giddens, Damien M. Bolton, Barrett E. Cowan, Anthony L. Cantwell, Kevin T. McVary, Alexis E. Te, Shahram S. Gholami, William G. Moseley, Peter T. Chin, William T. Dowling, Sheldon J. Freedman, Peter F. Incze, K. Scott Coffield, Sean Herron, Prem Rashid, Daniel B. Rukstalis

Research output: Contribution to journalArticle

49 Scopus citations

Abstract

Introduction: To report the five year results of a prospective, multi-center, randomized, blinded sham control trial of the Prostatic Urethral Lift (PUL) in men with bothersome lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). Materials and methods: At 19 centers in North America and Australia, 206 subjects ≥ 50 years old with International Prostate Symptom Score (IPSS ) > 12, peak flow rate (Qmax) ≤ 12 mL/s, and prostate volume 30 cc-80 cc were randomized 2:1 to the PUL procedure or blinded sham control. In PUL permanent UroLift implants are placed to hold open the lateral lobes of the prostate to reduce urinary obstruction. After randomized comparison at 3 months and the only opportunity to add more PUL implants, PUL patients were followed to 5 years. LUTS severity (IPSS), quality of life (QOL), BPH Impact Index (BPHII), Qmax, sexual function, and adverse events were assessed throughout follow up. Results: IPSS improvement after PUL was 88% greater than that of sham at 3 months. LUTS and QOL were significantly improved by 2 weeks with return to preoperative physical activity within 8.6 days. Improvement in IPSS, QOL, BPHII, and Qmax were durable through 5 years with improvements of 36%, 50%, 52%, and 44% respectively. No difference was seen between Intent to Treat and Per Protocol populations. Surgical retreatment was 13.6% over 5 years. Adverse events were mild to moderate and transient. Sexual function was stable over 5 years with no de novo, sustained erectile or ejaculatory dysfunction. Conclusions: PUL offers rapid improvement in symptoms, QOL and flow rate that is durable to 5 years. These improvements were achieved with minimal use of a postoperative urinary catheter, rapid return to normal, and preservation of both erectile and ejaculatory function. Symptom improvement was commensurate with patient satisfaction. PUL offers a minimally invasive option in the treatment of LUTS due to BPH.

Original languageEnglish (US)
Pages (from-to)8802-8813
Number of pages12
JournalCanadian Journal of Urology
Volume24
Issue number3
StatePublished - Jun 1 2017

Keywords

  • BPH
  • Minimally invasive
  • Sexual function
  • Surgery
  • Surgical therapy

ASJC Scopus subject areas

  • Medicine(all)
  • Urology

Fingerprint Dive into the research topics of 'Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study'. Together they form a unique fingerprint.

  • Cite this

    Roehrborn, C., Barkin, J., Gange, S. N., Shore, N. D., Giddens, J. L., Bolton, D. M., Cowan, B. E., Cantwell, A. L., McVary, K. T., Te, A. E., Gholami, S. S., Moseley, W. G., Chin, P. T., Dowling, W. T., Freedman, S. J., Incze, P. F., Coffield, K. S., Herron, S., Rashid, P., & Rukstalis, D. B. (2017). Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study. Canadian Journal of Urology, 24(3), 8802-8813.